Researchers used tissue and liquid biopsy data to identify DNA methylation subgroups in pleural mesothelioma that may predict outcomes on standard immunotherapy regimens. The work, published in Nature Genetics, aims to help stratify patients receiving checkpoint inhibitor combinations by uncovering methylation patterns tied to response. The retrospective analysis evaluated samples from 91 patients treated prior to immunotherapy, with the authors linking differential survival behavior to immunotherapy benefit variability. The report notes that in the supportive Phase III approval context, immunotherapy plus chemotherapy improved median overall survival overall, but benefit was concentrated in specific tumor subgroups. Prospective validation is the next step, with the researchers now planning forward-looking studies to confirm whether methylation subgrouping can guide treatment selection beyond current clinicopathologic signals.